{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T03:01:14Z","timestamp":1760151674238,"version":"build-2065373602"},"reference-count":35,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Instituto de Investigaci\u00f3n Sanitaria La Fe","award":["2019-052-1"],"award-info":[{"award-number":["2019-052-1"]}]},{"name":"Jazz Pharmaceuticals (Ireland)","award":["."],"award-info":[{"award-number":["."]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Information regarding the impact on healthcare systems of secondary acute myeloid leukemia (sAML) is scarce. Methods: A retrospective review of medical charts identified patients aged 60\u201375 years with sAML between 2010 and 2019. Patient information was collected from diagnosis to death or last follow-up. Outpatient resource use, reimbursement, frequency and duration of hospitalization, and transfusion burden were assessed. Forty-six patients with a median age of 64 years were included. Anthracycline plus cytarabine regimens were the most common induction treatment (39 patients, 85%). The ratio of the total days hospitalized between the total follow-up was 29%, with a sum of 204 hospitalizations (average four\/patient; average duration 21 days). The total average reimbursement was EUR 90,008 per patient, with the majority (EUR 77,827) related to hospital admissions (EUR 17,403\/hospitalization). Most hospitalizations (163, mean 22 days) occurred in the period before the first allogeneic hematopoietic stem cell transplant (alloHSCT), costing EUR 59,698 per patient and EUR 15,857 per hospitalization. The period after alloHSCT (in only 10 patients) had 41 hospitalizations (mean 21 days), and a mean reimbursement cost of EUR 99,542 per patient and EUR 24,278 per hospitalization. In conclusion, there is a high consumption of economic and healthcare resources in elderly patients with sAML receiving active treatments in Spain.<\/jats:p>","DOI":"10.3390\/cancers14081921","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:23:11Z","timestamp":1649722991000},"page":"1921","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Healthcare Resource Utilization among Patients between 60\u201375 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8804-3878","authenticated-orcid":false,"given":"Antonio","family":"Solana-Altabella","sequence":"first","affiliation":[{"name":"Pharmacy Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"},{"name":"Hematology and Hemotherapy, Instituto de Investigaci\u00f3n Sanitaria La Fe, 46026 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0369-5341","authenticated-orcid":false,"given":"Juan Eduardo","family":"Meg\u00edas-Vericat","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5444-5836","authenticated-orcid":false,"given":"Octavio","family":"Ballesta-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"},{"name":"Hematology and Hemotherapy, Instituto de Investigaci\u00f3n Sanitaria La Fe, 46026 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1785-5561","authenticated-orcid":false,"given":"Blanca","family":"Boluda","sequence":"additional","affiliation":[{"name":"Hematology and Hemotherapy, Instituto de Investigaci\u00f3n Sanitaria La Fe, 46026 Valencia, Spain"},{"name":"Hematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Cano","sequence":"additional","affiliation":[{"name":"Hematology and Hemotherapy, Instituto de Investigaci\u00f3n Sanitaria La Fe, 46026 Valencia, Spain"},{"name":"Hematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn","family":"Acu\u00f1a-Cruz","sequence":"additional","affiliation":[{"name":"Hematology and Hemotherapy, Instituto de Investigaci\u00f3n Sanitaria La Fe, 46026 Valencia, Spain"},{"name":"Hematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebeca","family":"Rodr\u00edguez-Veiga","sequence":"additional","affiliation":[{"name":"Hematology and Hemotherapy, Instituto de Investigaci\u00f3n Sanitaria La Fe, 46026 Valencia, Spain"},{"name":"Hematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Torres-Mi\u00f1ana","sequence":"additional","affiliation":[{"name":"Hematology and Hemotherapy, Instituto de Investigaci\u00f3n Sanitaria La Fe, 46026 Valencia, Spain"},{"name":"Hematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Sargas","sequence":"additional","affiliation":[{"name":"Hematology and Hemotherapy, Instituto de Investigaci\u00f3n Sanitaria La Fe, 46026 Valencia, Spain"},{"name":"Hematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1489-1177","authenticated-orcid":false,"given":"Miguel \u00c1.","family":"Sanz","sequence":"additional","affiliation":[{"name":"Hematology and Hemotherapy, Instituto de Investigaci\u00f3n Sanitaria La Fe, 46026 Valencia, Spain"},{"name":"Hematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmela","family":"Borrell-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"L\u00f3pez-Briz","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1800-6198","authenticated-orcid":false,"given":"Jos\u00e9 Luis","family":"Poveda-Andr\u00e9s","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8354-768X","authenticated-orcid":false,"given":"Javier","family":"De la Rubia","sequence":"additional","affiliation":[{"name":"Hematology and Hemotherapy, Instituto de Investigaci\u00f3n Sanitaria La Fe, 46026 Valencia, Spain"},{"name":"Hematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"},{"name":"School of Medicine and Dentistry, Catholic University of Valencia, 46010 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pau","family":"Montesinos","sequence":"additional","affiliation":[{"name":"Hematology and Hemotherapy, Instituto de Investigaci\u00f3n Sanitaria La Fe, 46026 Valencia, Spain"},{"name":"Hematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7540-4091","authenticated-orcid":false,"given":"David","family":"Mart\u00ednez-Cuadr\u00f3n","sequence":"additional","affiliation":[{"name":"Hematology and Hemotherapy, Instituto de Investigaci\u00f3n Sanitaria La Fe, 46026 Valencia, Spain"},{"name":"Hematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,11]]},"reference":[{"key":"ref_1","first-page":"937","article-title":"The incidence of secondary leukemias","volume":"84","author":"Leone","year":"1999","journal-title":"Haematologica"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","article-title":"Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study","volume":"33","author":"Medeiros","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.23908","article-title":"Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: A report from the Swedish Acute Leukemia Registry","volume":"90","author":"Nilsson","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4149\/neo_2010_02_170","article-title":"Secondary acute myeloid leukemia\u2014A single center experience","volume":"57","author":"Szotkowski","year":"2010","journal-title":"Neoplasma"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/ajh.23772","article-title":"Characteristics of acute myeloid leukemia with myelodysplasia-related changes: A retrospective analysis in a cohort of Chinese patients","volume":"89","author":"Xu","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1054\/bjoc.1999.1123","article-title":"Treatment, long-term outcome and prognostic variables in 214 unselected AML patients in Sweden","volume":"82","author":"Bodin","year":"2000","journal-title":"Br. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1182\/blood-2003-02-0434","article-title":"AML with 11q23\/MLL abnormalities as defined by the WHO classification: Incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases","volume":"102","author":"Schoch","year":"2003","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1365-2141.2009.07663.x","article-title":"Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials","volume":"145","author":"Wheatley","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1600-0609.2010.01464.x","article-title":"Reasons for treating secondary AML as de novo AML","volume":"85","author":"Kjeldsen","year":"2010","journal-title":"Eur. J. Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","article-title":"The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML","volume":"117","author":"Kayser","year":"2011","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3324\/haematol.2012.066100","article-title":"Survival for older patients with acute myeloid leukemia: A population-based study","volume":"97","author":"Oran","year":"2012","journal-title":"Haematologica"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/imj.12169","article-title":"Acute myeloid leukaemia in Western Australia 1991\u20132005: A retrospective population-based study of 898 patients regarding epidemiology, cytogenetics, treatment and outcome","volume":"43","author":"Gangatharan","year":"2013","journal-title":"Intern. Med. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00277-015-2351-x","article-title":"Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States","volume":"94","author":"Medeiros","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1016\/S0140-6736(10)62105-8","article-title":"Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: A web-based application for prediction of outcomes","volume":"376","author":"Krug","year":"2010","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1200\/JCO.2011.35.7525","article-title":"Prediction of Early Death after Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia with Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment","volume":"29","author":"Walter","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.beha.2006.10.006","article-title":"Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?","volume":"20","author":"Larson","year":"2007","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1182\/bloodadvances.2021005335","article-title":"Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: A PETHEMA registry study","volume":"6","author":"Serrano","year":"2022","journal-title":"Blood Adv."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1182\/blood-2013-12-540971","article-title":"Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine\/daunorubicin, vs cytarabine\/daunorubicin in older adults with untreated AML","volume":"123","author":"Lancet","year":"2014","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients with Newly Diagnosed Secondary Acute Myeloid Leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Estey","year":"2017","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"721","DOI":"10.6004\/jnccn.2019.0028","article-title":"Acute Myeloid Leukemia, Version 3. 2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Tallman","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s41669-018-0098-8","article-title":"Time and Cost of Hospitalisation for Salvage Therapy in Adults with Philadelphia Chromosome-Negative B Cell Precursor Relapsed or Refractory Acute Lymphoblastic Leukaemia in Spain","volume":"3","author":"Boluda","year":"2019","journal-title":"PharmacoEconomics-Open"},{"key":"ref_24","unstructured":"(2022, February 17). An\u00e1lisis y desarrollo de los GDR en el Sistema Nacional de Salud. Available online: https:\/\/www.sanidad.gob.es\/estadEstudios\/estadisticas\/docs\/analisis.pdf."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1007\/s12325-019-01003-7","article-title":"Economic and Clinical Burden of Relapsed and\/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer Database","volume":"36","author":"Pandya","year":"2019","journal-title":"Adv. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1080\/13696998.2018.1513847","article-title":"Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemia","volume":"21","author":"Hagiwara","year":"2018","journal-title":"J. Med. Econ."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/ejh.13604","article-title":"Healthcare resource utilization in adult patients with relapsed\/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain","volume":"106","author":"Boluda","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1080\/13696998.2020.1744613","article-title":"Healthcare resource utilization in a phase 3 study of CPX-351 in patients with newly diagnosed high-risk\/secondary acute myeloid leukemia","volume":"23","author":"Villa","year":"2020","journal-title":"J. Med. Econ."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1080\/13696998.2018.1425209","article-title":"Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations","volume":"21","author":"Stein","year":"2018","journal-title":"J. Med. Econ."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.clinthera.2018.03.012","article-title":"Burden of Acute Myeloid Leukemia among Older, Newly Diagnosed Patients: Retrospective Analysis of Data from the 2010\u20132012 Medicare Limited Data Set","volume":"40","author":"Sacks","year":"2018","journal-title":"Clin. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/03007995.2016.1267615","article-title":"Acute myeloid leukemia: A retrospective claims analysis of resource utilization and expenditures for newly diagnosed patients from first-line induction to remission and relapse","volume":"33","author":"Irish","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2016.4858","article-title":"Association of Risk Factors, Mortality, and Care Costs of Adults with Acute Myeloid Leukemia with Admission to the Intensive Care Unit","volume":"3","author":"Halpern","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_33","unstructured":"(2022, February 17). Expansion\u2014Diario Econ\u00f3mico e Informaci\u00f3n de Mercado Datosmacro.com\u2014Expansion. Available online: https:\/\/datosmacro.expansion.com\/estado\/gasto\/salud\/."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.leukres.2012.09.018","article-title":"The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands","volume":"37","author":"Leunis","year":"2013","journal-title":"Leuk. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2147\/CEOR.S222879","article-title":"Cost-Effectiveness of Midostaurin in The Treatment of Acute Myeloid Leukemia with The FLT3 Mutation in Spain","volume":"11","author":"Arenaza","year":"2019","journal-title":"Clin. Outcomes Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/8\/1921\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:51:28Z","timestamp":1760136688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/8\/1921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,11]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["cancers14081921"],"URL":"https:\/\/doi.org\/10.3390\/cancers14081921","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2022,4,11]]}}}